Call your doctor before leaving home if you think you’ve been exposed to COVID-19 or have symptoms

Due to the presence of COVID-19 in our community, visitor restrictions are in place for all Duke clinics and hospitals. For your safety and the safety of others, we recommend patients do not bring a visitor to Duke clinics, if at all possible. If a visitor must accompany a patient, only one individual over 12 years of age is allowed. Patients and visitors will be screened for symptoms upon arrival. Individuals with flu-like symptoms are not allowed. View the complete list of Visitor Restrictions.

Effective immediately, Duke Health is prioritizing and rescheduling some non-emergent or non-critical surgeries, procedures, and appointments. Check our COVID-19 (Coronavirus) page for updates.

ARRAY-BRAF (Brain Cancer) - Clinical Trial

What is the Purpose of this Study?

We are doing this study to learn if high-dose regimens of the study drugs (encorafenib and binimetinib) are better for people versus the standard dose.
What is the Condition Being Studied?
Melanoma with the BRAFV600 mutation (that has spread to the brain)

Who Can Participate in the Study?

Adults with Melanoma that contains the BRAFV600 mutation (that has spread to the brain)

Age Group

What is Involved?

If you choose to join this study, you will:
- Have a physical
- Have blood tests
- Complete CT and MRI Scans (body scans)
- Take the study drugs (Encorafenib and Binimetinib by mouth in 28 day cycles (up to 2 years)
- Complete follow-up visits every 12 weeks after stopping study drug

Study Details

Full Title
A Phase 2, Open-Label, Randomized, Multicenter Trial of Encorafenib + Binimetinib Evaluating a Standard-dose and a High-dose Regimen in Patients With BRAFV600-Mutant Melanoma Brain Metastasis
Principal Investigator
Medical Oncologist
Protocol Number
IRB: PRO00102665
NCT: NCT03911869
Phase II
Contact the Duke Recruitment Innovation Center